Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Enhanced killing of human small cell lung cancer by hyperthermia and indium-111-bleomycin complex

Journal Article · · Journal of Surgical Oncology; (USA)
;  [1]
  1. Univ. of Kentucky Medical Center, Lexington (USA)
Indium-111-bleomycin complex ({sup 111}In-BLMC) is a radiopharmaceutical agent that produces tumor regression in mouse glioma in vivo and kills human small cell lung cancer (SCLC) cells in vitro. The interaction between hyperthermia and {sup 111}In-BLMC against human SCLC (N417) cells was studied for bleomycin (BLM) (15 micrograms/ml) or {sup 111}In-BLMC (40-50 microCi carried by 15 micrograms BLM/ml) for 5 min or 1.5, 2, or 4 hr at 37{degrees}C or 43{degrees}C exposures. Cell survival was determined by colony formation in soft agarose. There was a synergistic effect for {sup 111}In-BLMC and hyperthermia for cell killing. At 37{degrees}C, the percent survival of N417 cells for BLM alone was 25.9%, and for {sup 111}In-BLMC it was 13.2%; at 43 degrees C, survival was 5.3% for BLM alone and 1.2% for {sup 111}In-BLMC by a 4 hr treatment. Effectiveness was greater when {sup 111}In-BLMC was combined with hyperthermia.
OSTI ID:
6749160
Journal Information:
Journal of Surgical Oncology; (USA), Journal Name: Journal of Surgical Oncology; (USA) Vol. 44:1; ISSN JSONA; ISSN 0022-4790
Country of Publication:
United States
Language:
English